MyFinsight
Home
Blog
About
Thereafter
$65,232K
2030
$5,544K
2029
$5,544K
2028
$5,544K
2027
$5,544K
2026
$2,772K
Thereafter
$6,824K
2030
$1,463K
2029
$1,463K
2028
$1,463K
2027
$1,463K
2026
$731K
Thereafter
$5,293K
2030
$941K
2029
$941K
2028
$941K
2027
$941K
2026
$471K
Marketable securities
$114,147K
(-53.33%↓ Y/Y)
Accounts receivable, net
$59,692K
(32.67%↑ Y/Y)
Cash and cash
equivalents
$55,882K
(-31.00%↓ Y/Y)
Prepaid expenses and
other current assets
$33,085K
(48.97%↑ Y/Y)
Inventory
$1,678K
(-22.64%↓ Y/Y)
PONVORY
$90,180K
Hetlioz
$13,407K
NEREUS
$9,528K
Total current assets
$264,484K
(-33.03%↓ Y/Y)
Intangible assets, net
$113,115K
(2.28%↑ Y/Y)
Operating lease
right-of-use assets
$14,598K
(203.87%↑ Y/Y)
Non-current inventory and
other
$10,920K
(13.50%↑ Y/Y)
Finance lease
right-of-use assets
$6,772K
(29.14%↑ Y/Y)
Property and equipment,
net
$2,578K
(6.53%↑ Y/Y)
Total assets
$412,467K
(-33.98%↓ Y/Y)
Total liabilities and
stockholders equity
$412,467K
(-33.98%↓ Y/Y)
Total stockholders
equity
$220,185K
(-54.73%↓ Y/Y)
Total liabilities
$192,282K
(38.92%↑ Y/Y)
Accumulated deficit
-$505,846K
(-118.99%↓ Y/Y)
Additional paid-in capital
$725,933K
(1.26%↑ Y/Y)
Total current
liabilities
$164,026K
(35.01%↑ Y/Y)
Operating lease
non-current liabilities
$15,027K
(287.59%↑ Y/Y)
Other non-current
liabilities
$10,054K
(0.86%↑ Y/Y)
Finance lease
non-current liabilities
$3,175K
(2.98%↑ Y/Y)
Common stock, 0.001 par
value 150,000,000...
$60K
(1.69%↑ Y/Y)
Accumulated other
comprehensive income
$38K
(-90.40%↓ Y/Y)
Product revenue
allowances
$94,032K
(46.08%↑ Y/Y)
Accounts payable and
accrued liabilities
$69,994K
(22.54%↑ Y/Y)
Back
Back
Balance Sheet
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)
source: myfinsight.com